Abstract
Small ubiquitin-like modifiers (SUMO) and ubiquitin are frequent post-translational modifications of proteins that play pivotal roles in all cellular processes. We previously reported mass spectrometry-based proteomics methods that enable profiling of lysines modified by endogenous SUMO or ubiquitin in an unbiased manner, without the need for genetic engineering. Here we investigated the applicability of precursor mass filtering enabled by MaxQuant.Live to our SUMO and ubiquitin proteomics workflows, which efficiently avoided sequencing of precursors too small to be modified but otherwise indistinguishable by mass-to-charge ratio. Using precursor mass filtering, we achieved a much higher selectivity of modified peptides, ultimately resulting in up to 30% more SUMO and ubiquitin sites identified from replicate samples. Real-time exclusion of unmodified peptides by MQL resulted in 90% SUMO-modified precursor selectivity from a 25% pure sample, demonstrating great applicability for digging deeper into ubiquitin-like modificomes. We adapted the precursor mass filtering strategy to the new Exploris 480 mass spectrometer, achieving comparable gains in SUMO precursor selectivity and identification rates. Collectively, precursor mass filtering via MQL significantly increased identification rates of SUMO- A nd ubiquitin-modified peptides from the exact same samples, without the requirement for prior knowledge or spectral libraries.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Journal of proteome research |
Vol/bind | 20 |
Udgave nummer | 4 |
Sider (fra-til) | 2042-2055 |
ISSN | 1535-3893 |
DOI | |
Status | Udgivet - apr. 2021 |
Bibliografisk note
Funding Information:The work carried out in this study was in part supported by the Novo Nordisk Foundation Center for Protein Research, the Novo Nordisk Foundation (grant agreement numbers NNF14CC0001 and NNF13OC0006477), Danish Council of Independent Research (grant agreement numbers 4002-00051, 4183-00322A, 8020-00220B and 0135-00096B), and The Danish Cancer Society (grant agreement R146-A9159-16-S2). The proteomics technology applied was part of a project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement EPIC-XS-823839. We would like to thank members of the NNF-CPR Mass Spectrometry Platform for instrument support and technical assistance. B.B. would like to acknowledge the Danish National Research Foundation (DNRF grant agreement number 141 to ATLAS) and the Danish Council for Technology and Production Sciences (DFF, grant agreement number 8022-00051).
Publisher Copyright:
© 2020 American Chemical Society. All rights reserved.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.